Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Schmidt, Amand F.; Holmes, Michael V.; Preiss, David; Swerdlow, Daniel I.; Denaxas, Spiros; Fatemifar, Ghazaleh; Faraway, Rupert; Finan, Chris; Valentine, Dennis; Fairhurst-Hunter, Zammy; Hartwig, Fernando Pires; Horta, Bernardo Lessa; Hypponen, Elina; Power, Christine; Moldovan, Max; van Iperen, Erik; Hovingh, Kees; Demuth, Ilja; Norman, Kristina; Steinhagen-Thiessen, Elisabeth; Hancock, Stephen; Attia, John; Holliday, Elizabeth; Scott, Rodney; Teumer, A; Baumeister, S; Doerr, M; Lerch, MM; Voelker, U; Voelzke, H; Ward, J; Pell, JP; Meade, T; Christophersen, IE; Maitland-van der Zee, AH; Baranova, EV; Young, R; Ford, I; Campbell, A; Padmanabhan, S; Bots, ML; Grobbee, DE; Froguel, P; Thuillier, D; Roussel, R; Bonnefond, A; Cariou, B; Smart, M; Bao, Y; Kumari, M; Mahajan, A; Hopewell, JC; Seshadri, S; Dale, C; Costa, RPE; Ridker, PM; Chasman, DI; Reiner, AP; Ritchie, MD; Lange, LA; Cornish, AJ; Dobbins, SE; Hemminki, K; Kinnersley, B; Sanson, M; Labreche, K; Simon, M; Bondy, M; Law, P; Speedy, H; Allan, J; Li, N; Went, M; Weinhold, N; Morgan, G; Sonneveld, P; Nilsson, B; Goldschmidt, H; Sud, A; Engert, A; Hansson, M; Hemingway, H; Asselbergs, FW; Patel, RS; Keating, BJ; Sattar, N; Houlston, R; Casas, JP; Hingorani, AD; Demuth, Juri; Bertram, L; Lill, CM; Coassin, S; Willeit, J; Kiechl, S; Willeit, K; Mason, D; Wright, J; Morris, R; Wanamethee, G; Whincup, P; Ben-Shlomo, Y; McLachlan, S; Price, JF; Kivimaki, M; Welch, C; Sanchez-Galvez, A; Marques-Vidal, P; Nicolaides, A; Panayiotou, AG; Onland-Moret, NC; van der Schouw, YT; Matullo, G; Fiorito, G; Guarrera, S; Sacerdote, C; Wareham, NJ; Langenberg, C; Scott, RA; Luan, J; Bobak, M; Malyutina, S; Pajak, A; Kubinova, R; Tamosiunas, A; Pikhart, H; Grarup, N; Pedersen, O; Hansen, T; Linneberg, A; Jess, T; Cooper, J; Humphries, SE; Brilliant, M; Kitchner, T; Hakonarson, H; Carrell, DS; McCarty, CA; Lester, KH; Larson, EB; Crosslin, DR; de Andrade, M; Roden, DM; Denny, JC; Carty, C; Schofield, P; O'Donnell, M; Yusuf, S; Chong, M; Pare, G; van der Harst, P; Said, MA; Eppinga, RN; Verweij, N; Snieder, H; Christen, T; Mook-Kanamori, DO; Gustafsson, S; Lind, L; Ingelsson, E; Pazoki, R; Franco, O; Hofman, A; Uitterlinden, A; Dehghan, A

Title: Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Creator: Schmidt, Amand F.; Holmes, Michael V.; Preiss, David; Swerdlow, Daniel I.; Denaxas, Spiros; Fatemifar, Ghazaleh; Faraway, Rupert; Finan, Chris; Valentine, Dennis; Fairhurst-Hunter, Zammy; Hartwig, Fernando Pires; Horta, Bernardo Lessa; Hypponen, Elina; Power, Christine; Moldovan, Max; van Iperen, Erik; Hovingh, Kees; Demuth, Ilja; Norman, Kristina; Steinhagen-Thiessen, Elisabeth; Hancock, Stephen; Attia, John; Holliday, Elizabeth; Scott, Rodney; Teumer, A; Baumeister, S; Doerr, M; Lerch, MM; Voelker, U; Voelzke, H; Ward, J; Pell, JP; Meade, T; Christophersen, IE; Maitland-van der Zee, AH; Baranova, EV; Young, R; Ford, I; Campbell, A; Padmanabhan, S; Bots, ML; Grobbee, DE; Froguel, P; Thuillier, D; Roussel, R; Bonnefond, A; Cariou, B; Smart, M; Bao, Y; Kumari, M; Mahajan, A; Hopewell, JC; Seshadri, S; Dale, C; Costa, RPE; Ridker, PM; Chasman, DI; Reiner, AP; Ritchie, MD; Lange, LA; Cornish, AJ; Dobbins, SE; Hemminki, K; Kinnersley, B; Sanson, M; Labreche, K; Simon, M; Bondy, M; Law, P; Speedy, H; Allan, J; Li, N; Went, M; Weinhold, N; Morgan, G; Sonneveld, P; Nilsson, B; Goldschmidt, H; Sud, A; Engert, A; Hansson, M; Hemingway, H; Asselbergs, FW; Patel, RS; Keating, BJ; Sattar, N; Houlston, R; Casas, JP; Hingorani, AD; Demuth, Juri; Bertram, L; Lill, CM; Coassin, S; Willeit, J; Kiechl, S; Willeit, K; Mason, D; Wright, J; Morris, R; Wanamethee, G; Whincup, P; Ben-Shlomo, Y; McLachlan, S; Price, JF; Kivimaki, M; Welch, C; Sanchez-Galvez, A; Marques-Vidal, P; Nicolaides, A; Panayiotou, AG; Onland-Moret, NC; van der Schouw, YT; Matullo, G; Fiorito, G; Guarrera, S; Sacerdote, C; Wareham, NJ; Langenberg, C; Scott, RA; Luan, J; Bobak, M; Malyutina, S; Pajak, A; Kubinova, R; Tamosiunas, A; Pikhart, H; Grarup, N; Pedersen, O; Hansen, T; Linneberg, A; Jess, T; Cooper, J; Humphries, SE; Brilliant, M; Kitchner, T; Hakonarson, H; Carrell, DS; McCarty, CA; Lester, KH; Larson, EB; Crosslin, DR; de Andrade, M; Roden, DM; Denny, JC; Carty, C; Schofield, P; O'Donnell, M; Yusuf, S; Chong, M; Pare, G; van der Harst, P; Said, MA; Eppinga, RN; Verweij, N; Snieder, H; Christen, T; Mook-Kanamori, DO; Gustafsson, S; Lind, L; Ingelsson, E; Pazoki, R; Franco, O; Hofman, A; Uitterlinden, A; Dehghan, A
Relation: BMC Cardiovascular Disorders Vol. 19, Issue 1, no. 240
Publisher Link: http://dx.doi.org/10.1186/s12872-019-1187-z
Publisher: BioMed Central Ltd
Resource Type: journal article
Date: 2019
Description: Background: We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared findings with recent trials of pharmacological inhibitors of PCSK9. Methods: Published and individual participant level data (300,000+ participants) were combined to construct a weighted PCSK9 gene-centric score (GS). Seventeen randomized placebo controlled PCSK9 inhibitor trials were included, providing data on 79,578 participants. Results were scaled to a one mmol/L lower LDL-C concentration. Results: The PCSK9 GS (comprising 4 SNPs) associations with plasma lipid and apolipoprotein levels were consistent in direction with treatment effects. The GS odds ratio (OR) for myocardial infarction (MI) was 0.53 (95% CI 0.42; 0.68), compared to a PCSK9 inhibitor effect of 0.90 (95% CI 0.86; 0.93). For ischemic stroke ORs were 0.84 (95% CI 0.57; 1.22) for the GS, compared to 0.85 (95% CI 0.78; 0.93) in the drug trials. ORs with type 2 diabetes mellitus (T2DM) were 1.29 (95% CI 1.11; 1.50) for the GS, as compared to 1.00 (95% CI 0.96; 1.04) for incident T2DM in PCSK9 inhibitor trials. No genetic associations were observed for cancer, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, or Alzheimer’s disease – outcomes for which large-scale trial data were unavailable. Conclusions: Genetic variation at the PCSK9 locus recapitulates the effects of therapeutic inhibition of PCSK9 on major blood lipid fractions and MI. While indicating an increased risk of T2DM, no other possible safety concerns were shown; although precision was moderate.
Subject: genetic association studies; Mendelian randomisation; LDL-cholesterol; phenome-wide association scan; SDG 3; Sustainable Development Goals
Identifier: http://hdl.handle.net/1959.13/1443144
Identifier: uon:41899
Identifier: ISSN:1471-2261
Language: eng
Reviewed

Hits: 97838
Visitors: 97564
Downloads: 1

Collections

Goal 3: Good Health and Well-Being

		Thumbnail	File	Description	Size	Format